A Phase I Study of PRT1419 in People with Blood Cancers


Full Title

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 in Patients with Relapsed/Refractory Hematologic Malignancies


The purpose of this study is to find the highest dose of the investigational drug PRT1419 that can be given safely in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has either come back after treatment or has not responded to treatment.

PRT1419 works by blocking the protein MCL1, which is increased in people with AML, MDS, and some other blood cancers. MCL1 plays a role in protecting cancer cells and may help cancer cells resist approved treatments such as chemotherapy or venetoclax. By blocking MCL1, PRT1419 may slow or stop the growth of cancer cells. It is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have recurrent or persistent AML or MDS.
  • Patients should recover from the serious side effects of prior therapies before receiving PRT1419.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Aaron Goldberg at 646-608-3752.





Disease Status

Relapsed or Refractory